- United States
- /
- Biotech
- /
- NasdaqGS:ATRA
Atara Biotherapeutics Inc (NASDAQ:ATRA): What Can We Expect From This High Growth Stock?
Analysts' outlook for next year seems pessimistic, with earnings becoming even more negative, generating -US$149.57M in 2019. Moreover, earnings are expected to fall off in the following year, before bouncing back up again to -US$151.53M in 2021.
While it’s useful to understand the growth rate each year relative to today’s value, it may be more valuable gauging the rate at which the earnings are moving every year, on average. The advantage of this technique is that we can get a bigger picture of the direction of Atara Biotherapeutics's earnings trajectory over the long run, irrespective of near term fluctuations, fluctuate up and down. To compute this rate, I've appended a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 14.25%. This means, we can expect Atara Biotherapeutics will grow its earnings by 14.25% every year for the next couple of years.
Next Steps:
For Atara Biotherapeutics, there are three key factors you should look at:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does ATRA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of ATRA? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About NasdaqGS:ATRA
Atara Biotherapeutics
Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
Good value with moderate growth potential.
Market Insights
Community Narratives
